ZEISS Webinar

Use of fluorescence in treating brain tumors

Use of fluorescence in treating brain tumors

Use of fluorescence is becoming increasingly commonplace today for brain tumor surgery. Three well-known US neurosurgeons will present their experiences on the use of fluorescence visualization in various aspects during brain tumor procedures.

Date & Time:

Thursday, September 17, 2020 | 9:00 AM – 10:00 AM (PDT) / 12:00 PM – 1:00 PM (EDT) / 6:00 – 7:00 PM (CEST)


About the Speakers:

Dr. Lee is Professor of Neurosurgery and Otolaryngology at the University of Pennsylvania. Having completed residency training at the University of Pittsburgh, he started as an Assistant Professor and has risen through the ranks at the University of Pennsylvania. He has a special interest in endoscopic approaches to the skull base, especially of the cerebellopontine angle. In addition, he has pioneered the use of Second Window Indocyanine Green aka. TumorGlow™ for brain tumor surgery.

Presentation title:
Near Infrared Intraoperative Molecular Imaging for Brain Tumor Surgery

John Y. K. Lee, MD, MSCE

Jeffrey Bruce, MD

Jeffrey N. Bruce, M.D., graduated With Distinction from the University of Virginia and received his medical degree from Rutgers-Robert Wood Johnson Medical School. He was a medical staff fellow in the Surgical Neurology Branch of the N.I.H. before completing a neurosurgery residency at the Neurological Institute of New York, Columbia University. He remained on staff and is currently the Edgar M. Housepian Professor of Neurological Surgery at Columbia University’s College of Physicians and Surgeons, where he serves as Vice-Chairman, Co-Director of the Brain Tumor Center, and Director of the Bartoli Brain Tumor Research Laboratory.

He has authored over 200 publications as leader of an NIH-funded translational brain tumor research effort with interests in glioma immunotherapy, progenitor cell biology and drug delivery systems. Clinically he specializes in surgical neuro-oncology, with particular interests in skull base, pineal tumors and pituitary tumors. His numerous awards include the Teacher Recognition Award from Columbia University, the Physician of the Year from CancerCare, induction into the Alpha Omega Alpha honorary medical society, Distinguished Service Award from the Society of University Neurosurgeons and the Distinguished Alumni Award from Rutgers-RWJMS.

He has previously served as Chairman of the American Board of Neurological Surgery, Chairman of the Joint Section on Tumors for the AANS/CNS, Vice-President of the American Academy of Neurological Surgeons, President of the Society of University Neurosurgeons and President of the New York Society for Neurosurgery. He is a member of several editorial boards including Journal of Neuro-oncology (Associate Editor), Neurosurgery, and Journal of Surgical Education.

Presentation title:
Use of Fluorescein for Brain Tumor Surgery

Dr. Hadjipanayis is a Professor of Neurosurgery and Oncological Sciences at the Icahn School of Medicine at Mount Sinai. He serves as Chair of the Department of Neurosurgery at Mount Sinai Union Square/Beth Israel and Director of Neurosurgical Oncology for the Mount Sinai Health System. He has devoted his entire career to the treatment of brain tumor patients. He is Director of the Mount Sinai Brain Tumor Nanotechnology Laboratory in the Tisch Cancer Institute where he studies novel therapeutics targeting brain tumors. Dr. Hadjipanayis helped lead the development and FDA approval of 5-ALA (Gleolan) and fluorescence-guided surgery (FGS) for malignant brain tumors in the US.

Presentation title:
5-ALA Fluorescence-Guided Surgery for Brain Tumors after FDA Approval

Constantinos (Costas) G. Hadjipanayis, MD, PhD


Register for the Webinar

Unable to load form.

The statements of the speakers reflect only their personal opinions and do not necessarily reflect the opinions of any institution with which they are affiliated. The speakers have a contractual or other financial relationship with Carl Zeiss Meditec, Inc. and its affiliates and have received financial support.